Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Rhea-AI Summary
Arvinas (Nasdaq: ARVN) will report fourth quarter and full year 2025 financial results on February 24, 2026. Management will review results and provide a corporate update via a live webcast at 8:00 a.m. ET.
The webcast is available under “Events and Presentations” on Arvinas’ investor website, and a replay will be posted on www.arvinas.com after the event.
Positive
- None.
Negative
- None.
News Market Reaction – ARVN
On the day this news was published, ARVN declined 1.80%, reflecting a mild negative market reaction. This price movement removed approximately $14M from the company's valuation, bringing the market cap to $748M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
ARVN fell 1.56% with biotech peers OLMA, SAGE, NRIX, VSTM, and XNCR also down between 0.69% and 4.52%, indicating a broader negative sector tone rather than company-specific trading.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Leadership change | Neutral | -9.6% | CEO transition to Randy Teel with Houston moving to consulting role. |
| Feb 10 | Industry outlook | Positive | +1.1% | Report highlighting PROTAC market growth and Arvinas partnerships. |
| Nov 26 | Conference appearance | Neutral | +2.5% | Planned presentation at Piper Sandler healthcare conference. |
| Nov 24 | Clinical data update | Positive | +2.2% | Multiple SABCS presentations from vepdegestrant development program. |
| Nov 05 | Earnings and pipeline | Positive | +0.3% | Q3 2025 financials, strong cash, NDA acceptance and pipeline progress. |
Recent news has mostly been positive or neutral with price reactions generally aligning, except for a negative response to the CEO transition.
Over the last several months, Arvinas has reported multiple clinical and corporate milestones. Q3 2025 earnings on Nov 5, 2025 highlighted revenue of $41.9M, a net loss of $35.1M, cash of $787.6M, and a $100M repurchase program. Subsequent news included positive vepdegestrant data at major conferences and strong preclinical results for ARV-806, generally met with modestly positive price moves. The CEO transition announced on Feb 12, 2026 saw a -9.59% reaction. Today’s earnings-date announcement fits into this cadence of planned corporate communications.
Market Pulse Summary
This announcement sets expectations for Arvinas’ fourth quarter and full year 2025 results webcast on February 24, 2026. In recent quarters, updates have included cash levels of $787.6M, a $100M repurchase program, and progress on vepdegestrant and ARV‑806. Investors may focus on cash runway, collaboration revenue trends, and any changes to development timelines or commercialization plans, especially given the previously disclosed June 5, 2026 PDUFA date for vepdegestrant.
Key Terms
targeted protein degradation medical
AI-generated analysis. Not financial advice.
NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year 2025 financial results and provide a corporate update during a live webcast on Tuesday, February 24, 2026 at 8:00 a.m. ET.
The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
When will Arvinas (ARVN) report Q4 and full year 2025 results?
How can investors watch the Arvinas (ARVN) February 24, 2026 webcast?
Will Arvinas (ARVN) provide a replay of the February 24, 2026 webcast?
What will Arvinas (ARVN) cover during the February 24, 2026 webcast?
Where can shareholders find the Arvinas (ARVN) investor webcast materials after the event?
